Insulin icodec (Awiqli)
Once-weekly basal insulin analog · insulin class · sc weekly · Novo Nordisk
Top dose
titrated
HbA1c reduction
-1.55%
at week 52 · treatment policy
AE discontinuation
2.0%
Status
approved
Pivotal trial
- Trial
- ONWARDS-1
- Indication
- type 2 diabetes (insulin-naive)
- Duration
- 52 weeks
- ClinicalTrials.gov
- NCT04460885
- Sponsor
- Novo Nordisk
Notes
ONWARDS-1 (Rosenstock NEJM 2023): once-weekly icodec HbA1c -1.55% vs daily glargine U100 -1.35% in insulin-naive T2D at week 52, baseline 8.5%. The key tolerability axis for insulin is hypoglycemia, not AE-led discontinuation - icodec showed slightly higher level-2/3 hypoglycemia than glargine. Approved EU as Awiqli; first once-weekly basal insulin.